Senior insider sale
Chief Medical Officer at AVALO THERAPEUTICS, INC. — senior position signals high conviction
$262.3K
13.50K shares
What this filing means
DOYLE MITTIE plans to sell 13.50K shares of AVALO THERAPEUTICS, INC. valued at approximately $262.3K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 8/17/2026ACC: 0001950047-26-008276
Officer· Chief Medical Officer
Since Feb 2026
13.50K
Shares to sell
$262.3K
Approx. market value
5.04K
Acquired (3 months)
1
Planned
5 completed
Securities Acquired — Last 3 Months1
Exercise of Stock Options
Cash
8/17/2026
5.04KTotal acquired5.04K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
8/17/2026 | Exercise of Stock Options Cash | 5.04K | — |
| Total | 5.04K | ||
Planned & Completed Dispositions6
Completed
—Completed
Units to sell
679.00
Market value
$13.6K
8/10/2026
—Completed
Units to sell
1K
Market value
$20.0K
7/27/2026
—Completed
Units to sell
4.65K
Market value
$93.1K
6/30/2026
—Completed
Units to sell
1.45K
Market value
$26.1K
6/23/2026
—Completed
Units to sell
679.00
Market value
$10.9K
5/28/2026
Planned — Approximate Date
NASDAQPlanned
Units to sell
5.04K
Market value
$98.7K
8/17/2026
Total
Units
13.50K
Value
$262.3K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
8/10/2026 | 679.00 | $13.6K | — | Completed |
7/27/2026 | 1K | $20.0K | — | Completed |
6/30/2026 | 4.65K | $93.1K | — | Completed |
6/23/2026 | 1.45K | $26.1K | — | Completed |
5/28/2026 | 679.00 | $10.9K | — | Completed |
| Planned — Approximate Date | ||||
8/17/2026 | 5.04K | $98.7K | NASDAQ | Planned |
| Total | 13.50K | $262.3K | ||